摘要
目的观察参芪强心胶囊对慢性心力衰竭(CHF)患者心功能及血浆N端前脑钠肽(NT-pro BNP)与肿瘤坏死因子(TNF-α)水平的影响。方法把80例心衰患者随机分为对照组、治疗组。对照组常规抗心力衰竭治疗,治疗组加服参芪强心胶囊,2组疗程均为4周。观察两组临床疗效、左室收缩末期容积(LVESV),左室舒张末期容积(LVEDV)、左室射血分数(LVEF),检测治疗前后血浆NT-pro BNP、TNF-α水平。结果治疗组加用参芪强心胶囊后临床症状、左室收缩末期容积(LVESV),左室舒张末期容积(LVEDV)、左室射血分数(LVEF)、血浆N端前脑钠肽(NT-pro BNP)与肿瘤坏死因子(TNF-α)比治疗前明显改善,且明显优于对照组,并有显著性差异(P<0.05)。对照组治疗后临床疗效、左室收缩末期容积(LVESV),左室舒张末期容积(LVEDV)、左室射血分数(LVEF)、血浆N端前脑钠肽(NT-pro BNP)与肿瘤坏死因子(TNF-α)也有明显改善(P<0.05)。结论参芪强心胶囊治疗心衰能改善心衰患者临床疗效并降低左室收缩末期容积(LVESV),左室舒张末期容积(LVEDV)、血浆N端前脑钠肽(NT-pro BNP)与肿瘤坏死因子(TNF-α)水平,提高心衰患者左室射血分数(LVEF),改善左室功能。
Objective To investigate the effect of Shenqi Qiangxin Capsule on Heart Function and Serum N-terminal Pro-Brain Natriuretic Peptide Tumor Necrosis Factor-αin patients with chronic heart failure. Methods 80 patients were divided into the randomly treatment group and the control group. Both groups were treated with regular treatment for 4 weeks. Simultaneously the Shenqiqiangxin capsule was added into the treatment group. We observe the changes of Clinical Efficacy、LVESV、LVEDV、LVEF、NT-proBNP and TNF-αin 80 cases before and after therapy. Results Clinical Efficacy、LVESV、LVEDV、LVEF、NT-proBNP and TNF-αwere promoted after therapy in the two groups,the deference of reatment group was obvious than control group. Conclusion Shenqi Qiangxin capsule can improve the levels of LVESV、LVEDV、NT-proBNP and TNF-α in patients with chronic heart failure and improve clinical efficacy,inceased LVEF,improvement of left ventricular function.
出处
《云南中医学院学报》
2015年第3期47-50,共4页
Journal of Yunnan University of Traditional Chinese Medicine
基金
安徽省卫计委中医药科研课题(2014zy70)
